CatalystMarker
← board

ACB

distress 1/10 · well-funded / low risk
$2.660%today-57% from 52w high
auroramj.com1,028 employeesFounded 2013Edmonton, ABDrug Manufacturers - Specialty & Generic
Revenue
$321M
Liquidity
$129M
Runway
9.6 yrs
Shares 1y
-94%

Price & events

-38.6% over 6M
$2.58$3.50$4.43Jan 26Apr 26Jul 269.1M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+3.1%
1W
-6.7%
1M
-18.9%
3M
-40.0%
6M
-45.5%
1Y
-56.6%
2Y
-96.2%
5Y
-97.2%
All

Overview

Market Cap
$149.58M
Enterprise Value
$125.09M
Volume
83.66K
52 Week Range
$2.58 – $6.23
Total Shares
56.23M
Float Shares
61.54M
% Held by Insiders
1.27%
% Held by Institutions
9.70%
RVOL
0.07x
Beta
1.35

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 56,234,231 · 0 offerings/1y · 0 PIPEs
  • none
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

buy · target $ · analysts
  • no recent rating changes

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.